UBS initiates Celgene Corporation(NASDAQ:CELG) with a Buy and price target of $140. Robust top-line growth has become a rarity in large-cap biotech, and against that backdrop, Celgene has and should continue to stand out

Are you a swing trade and want to make quick return with favorable risk/reward ratio. Then, Traders Insights could be the right choice for you. We at Traders Insights provide daily swing trading alerts

Ocular Therapeutix Inc(NASDAQ:OCUL) receives CRL from the FDA regarding its NDA for DEXTENZA 0.4 mg, for intracanalicular use in the treatment of ocular pain occurring after ophthalmic surgery (5.17)
The concerns raised by the FDA pertain